Opdivo® (nivolumab) plus Yervoy® (ipilimumab) – Expanded indication, accelerated approval converted to traditional approval
April 11, 2025 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab) plus Yervoy (ipilimumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
Top